ESC 2022 – so far so similar for Farxiga and Jardiance
Astrazeneca’s SGLT2 matches Lilly and Boehringer’s rival in heart failure with preserved ejection fraction, but the big battle could be uptake.
Zantac burns big pharma
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?
The Sting is dead; long live the Sting
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
